

-2-

application) which was filed on September 23, 1994 and was pending when this application was filed on June 7, 1995. The '489 application and this application have a common inventor and thus with the filing of this amendment, applicants believe that all of the provisions of 35 USC §120 for claiming priority are satisfied.

With this added priority claim, this application claims priority from all of the prior applications which refer to the 5G1.1 antibody, the hybridoma which produces that antibody, and the hybridoma's deposit with the ATCC.

Submitted herewith is a Supplemental Declaration for the application.

This amendment is being submitted before or with the payment of the issue fee for this application (37 CFR §1.312). Entry of the amendment is respectfully requested.

Respectfully submitted,

Date: 10/30/01



Mark Farber
Reg. No. 34,159
Attorney for Applicants
Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410
(203) 272-2596